The facility will be constructed by renovating an existing 18,000ft² light manufacturing plant on a 4.2 acre in Shelton, US.
Id3A will design the overall facility as well as integrate separately constructed Clean Room Suite for cGMP production.
NanoViricides president Anil Diwan said, "This is critically important for our challenging project that specifies not only state-of-the-art facility requirements, but also cost sensitivity, space efficiency, and a high degree of energy efficiency."
The cGMP pilot plant is being designed to produce enough quantities of the drug needed for human clinical trials for each of the various nanoviricides drug candidates as the drugs progress into the clinical pipeline.